Via de sinalização da pi3ks como alvo molecular para terapia do glioblastoma: uma revisão

Abstract

Glioblastoma (GBM) is the most common type of cancer of the central nervous system (CNS). It currently accounts for about 2% of diagnosed malignant tumors, with 296,000 new cases reported each year. The gold standard treatment consists of surgical resection, radiotherapy and adjuvant chemotherapy that increase patients' survival by 15 months and few survive more than 5 years after diagnosis. New clinical and pre-clinical research aims to improve this prognosis by proposing the search for new drugs that act effectively in the elimination of cancer cells, circumventing problems such as resistance to treatment. One of the promising therapeutic strategies in the treatment of GBM is the inhibition of the phosphatidylinositol 3-kinases (PI3Ks) pathway, which is closely related to the tumor carcinogenesis process. This review sought to address the main scientific studies of synthetic or natural drug prototypes aimed at specific therapy co-directed via the PI3Ks pathway, against human glioblastoma.